Amylyx Pharmaceuticals announced an infusion of $135 million in Series C funds to support the late-stage development of the Boston-based company’s lead candidate, AMX0035, for amyotrophic lateral sclerosis (ALS).
AB Science announced the publication of long-term follow-up data showing that the company’s lead compound, masitinib, extended survival in Amyotrophic Lateral Sclerosis (ALS) patients by 25 months compared to placebo when treatment was started early.
Paris-based Ipsen inked a licensing deal with Sweden’s IRLAB for mesdopetam, a potential drug for Parkinson’s disease.
A study found potential in a novel gene therapy method to help children born with a rare genetic and neurodegenerative disorder, AADC deficiency.
Roche presented results from several Phase II and III trials at the 7th Congress of the European Academy of Neurology (EAN) Annual Meeting held virtually June 19-22.
Sanofi is halting a pivotal Phase II/III kidney disease trial for venglustat, a novel molecule designed to slow disease progression by inhibiting abnormal accumulation of glycosphingolipids.
Determined to take the company’s next-generation engineered cell therapies to the next level, BlueRock Therapeutics is teaming up with Senti Biosciences with futuristic medicines in mind.
Passage Bio Inc. and InformedDNA announced a collaboration to provide no-cost genetic counseling and testing for adults who have been diagnosed by their physicians with Frontotemporal Dementia (FTD).
Shanghai, China-based SciNeuro Pharmaceuticals and U.S.-based Eli Lilly inked an exclusive license deal to develop and commercialize alpha-synuclein targeted antibody treatments in Greater China
Swiss drugmakers Roche and Novartis each won European approval for drugs on March 30 in a sign that the rival Basel-based companies are increasingly competing for the same patients.
